

Date: 29th May 2015

To
The General Manager
Dept of Corporate Services
The Bombay Stock Exchange
Phiroj Jeejee bhoy Towers
Dalal Street, Mumbai

Dear Sir/Madam

Sub: Outcome of the board meeting - reg.

Pursuant to listing agreement, we are enclosing herewith the audited financial results for the year ended 31st March 2015 approved in the Board of directors meeting held on 29th May 2015 at 11.00 am in its register office

This is for your information and record.

Thanking you

Yours faithfully
for Venmax Drugs and Pharmaceuticals Ltd


N.V Narender
Managing Director

Encl: As above

Venmax Drugs And Pharmaceuticals Ltd.
Shed No. 22, Plot No. 84, Phase-1,
IDA Cherlapally, Hyderabad-500 051.


AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31 MARCH 2015

(Rs.in Lakhs)

Sl. No.	Particulars	Quarter ended		Year Ended	Year Ended
		31.03.15	31.03.14	31-03-2015	31-03-2014
		(Unaudited)	(Unaudited)	Audited	Audited
1	Income From operations				
	(a) Net Sales / Income from Operations(Net of excise duty)	48.60	20.64	254.73	61.62
	(b) Other Operating Income	-	-		
	Total Income from operations (net)	48.60	20.64	254.73	61.62
2	Expenses				
	a. Cost of materials consumed	47.79	18.53	249.48	56.26
	b. Purchase of stock-in-trade	-	-	146.74	
	c.Changes in inventories of finished goods, work-in-progress and stock-in-trade			-146.74	
	d. Employee benefits expense	4.34	3.60	6.86	27.96
	e. Depreciation and amortisation expense	-	-	-	1.16
	f. Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	8.71	5.33	9.75	19.92
	g. Other Manufacturing Expenses	-	-		
	h. Miscellaneous expenditure written off	-	-		
	Total expenses	60.84	27.46	266.09	105.30
3	Profit from operations before other Income, finance costs & exceptional Items (1 - 2)	(12.24)	(6.82)	(11.36)	(43.68)
4	Other Income	-	-	-	-
5	Profit / loss from ordinary activities before finance costs and exceptional items (3+4)	(12.24)	(6.82)	(11.36)	(43.68)
6	Finance costs	0.09	-	0.09	1.38
7	Profit / loss from ordinary activities after finance costs but before exceptional items	(12.33)	(6.82)	(11.45)	(45.06)
8	Exceptional Items				
9	Profit /(Loss) from ordinary activities before Tax (7 + 8)	(12.33)	(6.82)	(11.45)	(45.06)
10	Tax Expense	3.61	-	3.61	(52.45)
11	Net Profit/(Loss) from ordinary activities after Tax (9 +10)	(8.72)	(6.82)	(7.84)	(97.51)
12	Extraordinary items (net of tax expense)		(290.17)		(132.24)
13	Net Profit / (Loss) for the period (11 + 12)	(8.72)	(296.99)	(7.84)	(229.75)
14	Share of profit / (loss) of associates*	-	-	-	-
15	Minority interest*	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	-	-	-	-
17	Paid up equity share capital (Face value of Rs.10 each)	523.89	523.89	523.89	523.89
18	Reserves excluding Revaluation Reserves as per balance previous accounting year			(490.07)	(482.23)

For VENMAX DRUGS AND PHARMACEUTICALS LTD.

Noor
Managing Director



Venmax Drugs And Pharmaceuticals Ltd.
Shed No. 22, Plot No. 84, Phase-1,
IDA Cherlapally, Hyderabad-500 051.



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs. 10/- each) (not annualised):	-	-	-	-
	(a) Basic	-	-	-	-
	(b) Diluted	-	-	-	-
19.ii	Earnings Per Share (EPS) (after extraordinary items)(of Rs. 10/- each) (not annualised):	-	-	-	-
	(a) Basic	-	-	-	-
	(b) Diluted	-	-	-	-
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of Shares	40,26,200	40,26,200	40,26,200	40,26,200
	- Percentage of shareholding	77%	77%	77%	77%
2	Promoters and Promoter Group Shareholding				
a)	Pledged / Encumbered	-	-	-	-
	- Number of shares	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter Group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the	-	-	-	-
b)	Non - encumbered	-	-	-	-
	- Number of shares	12,12,730	12,12,730	12,12,730	12,12,730
B	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	23%	23%	23%	23%
	Particulars	Quarter ended (31-03-2015)			
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter			NIL	
	Received during the quarter			NIL	
	Disposed of during the quarter			NIL	
	Remaining unresolved at the end of the quarter			NIL	

For VENMAX DRUGS AND PHARMACEUTICALS LTD.


Managing Director



Venmax Drugs And Pharmaceuticals Ltd.
Shed No. 22, Plot No. 84, Phase-1,
IDA Cherlapally, Hyderabad-500 051.



VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

Statement of Assets and Liabilities

Particulars		31-03-2015	31-03-2014
		Audited	Audited
I.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
(a)	Share capital	523.89	523.89
(b)	Reserves and surplus	(490.07)	(482.23)
3	Non-current liabilities		
(a)	Long-term borrowings	150.15	140.27
4	Current liabilities		
(a)	Short-term borrowings	0.00	0.00
(b)	Trade payables	163.98	17.05
(c)	Other current liabilities	0.79	0.27
(d)	Short-term provisions	7.37	6.85
	TOTAL	356.11	206.10
II.	ASSETS		
	Non-current assets		
1	Fixed assets		
	Tangible assets	0.15	0.15
(b)	Non-current investments	0.58	0.58
(c)	Deferred tax assets (net)	84.48	80.87
(d)	Other Non-Current assets	100.51	100.51
2	Current assets		
(b)	Inventories	146.74	0.00
(c)	Trade receivables	14.35	21.20
(d)	Cash and cash equivalents	0.05	0.34
(e)	Other current assets	9.25	2.45
	TOTAL	356.11	206.10

1 The Financial Results have been reviewed by the Audit Committee and approved by the board of directors at their Meeting held on 29 May 2015

For VENMAX DRUGS AND PHARMACEUTICALS LTD.

Place: Hyderabad
Date: 29 May, 2015


Managing Director



Venmax Drugs And Pharmaceuticals Ltd.
Shed No. 22, Plot No. 84, Phase-1,
IDA Cherlapally, Hyderabad-500 051.